11 July 2016

IPO of Patheon N.V.

On 20 July 2016 the initial public offering of Patheon was priced at USD 21 per share and the shares will be listed on the New York Stock Exchange following closing on 26 July 2016. Patheon is a leading global provider of outsourced pharmaceutical development and manufacturing services and is one of the world’s largest contract drug manufacturers. It provides comprehensive solutions for both small molecule and large molecule biological pharmaceuticals. Following the IPO, Patheon has a market capitalization of around USD 3 billion. Patheon will sell 29,464,286 shares and DSM, as selling shareholder, will sell 4,761,905 of its 53.5 million shares in Patheon, resulting in approximately USD 618.75 million and USD 100 million in gross proceeds, respectively.

De Brauw Team: Paul Cronheim, Constantijn Voogt, Jan Marten van Dijk, Tijmen Klein Bronsvoort, Eline Viersen, Pim van Leersum, Olav Klaver, Lotte Boon, Johan Valk, Jan Willem Hoevers, Vivian Lee and Josse Klijnsma.

We keep track of you on our site with cookies, in order to offer the basic functionality of the website and generate user statistics on an anonymous basis to make our website more user-friendly. We do not use or share your data with third parties for advertising purposes.
Accept cookiesChange cookiesClick here for more information about our cookies.